The document discusses the challenges of innovation and product commercialization, highlighting high failure rates for new products, especially in startups. It introduces a 'Quicklook' process designed to assess and evaluate market opportunities and technology viability through structured research and customer engagement. Additionally, it outlines the development of a new dry vaccine technology aimed at improving immunization coverage in resource-limited settings.

1. 2014 ASQ
Innovation Conference
Toronto, Canada
1
Cheryl Tulkoff, ASQ CRE
University of Texas at Austin MSTC

2. 2
Idea
Research
Prototype
Research
Good idea
Bad Idea
$$$

Idea
vs.

3. 3
Rob Adams, A Good Hard Kick in the Ass: Basic Training for Entrepreneurs

4. More than 60% of new products fail
◦Established companies with deep resources
For start-ups, failure rate is 90%!
4
Adams, Rob (2010-03-09). If You Build It Will They Come: Three Steps to Test and Validate Any Market Opportunity (p. 2). Wiley. Kindle Edition.

5. Core elements of innovation:
◦Is different
◦Adds value
Quicklook process goals:
◦Reduce risk/failure by understanding the customer & markets
◦Avoid solution in search of a problem!
5
Brett Cornwell (1998). 'Quicklook' commercialization assessments. Innovation: Management, Policy & Practice:
What is desirable to users?
What is viable in the market?
What is possible with technology?
INNOVATION

6. Research snapshot
Quick GO/ NO GO evaluation of an opportunity
◦Determine whether to put more time, money, or effort into a technology
6

7. Step by step approach for evaluating a product, process, or idea
Identify potential markets
Identify users and potential licensees
Contact experts & companies
Identify barriers & opportunities
7

8. 8
Technology Description: Short, simple
Technology Benefits: User benefits, not function or features
Potential Markets: Pain, Opportunities
Market Interest: Level, Partners
Technology Development Status: Concept, Prototype, Product

9. 9
Intellectual Property Status: Patent, Trademark, Secret
Competing Technologies and Competitors
Barriers to Market Entry: Weaknesses, Threats
Recommendations: Go / No Go

10. 10
Primary Research
New Info
7-10 Productive Interviews
Secondary Research
Existing Info
Databases
Resources Alumni Industry Groups Publications

11. The Elevator Pitch
1.Who you are
How you’re connected: alumni, associate,
How you found them: LinkedIn, industry group, publication
2.Brief technology description
3.Why you want to talk to them
4.Why they want to talk to you
5.No sales pitches!
11

12. Hello Nick,
How are you? My name is Cheryl Tulkoff. I'm an engineer and current graduate student in the Masters of Science in Technology Commercialization program at UT Austin, TX. I found your information in the alumni directory and thought you might be able to help since Merck is the worldwide revenue leader in vaccines! I'm doing some market research for dry vaccine technology in support of a new patent pending process developed at UT.
My team and I are trying to understand the licensing process that companies like Merck use. What factors are important to companies like yours when they evaluate whether to license an opportunity. Do you see sufficient benefits in having vaccines that are not subject to cold chain requirements?
I’d love to ask you a few brief questions. It would take no longer than 15 minutes and my schedule is completely flexible.
12

13. 13
Voice of the Customer
Motivation
Buying Cycle
Decision Making
What’s Important
Technology Perception
Pain
Quality

14. 'After as little as 10-20 hours of research, staff have been able to provide reports to business managers which suggest the level of early interest in the technology; identifies potential partners; and points to potential ‘trouble spots'.'
14

15. Dry Vaccine Process
VAX Technology
MSTC 2015 Team 15
15

16. VAX Technology
•Pain
•Technology
•Barriers
•Market
•Next Steps
"One time power went out at our clinic and the refrigerator stopped working and we had to throw all of the vaccines out.“
Ben
Facility Unit Director
16
Proven Effect
Potential Effect
Tetanus
Hepatitis A
Diphtheria
Hepatitis B
Pertussis
Virus vaccines
Poliomyelitis

17. Pain
• 1.5 million children die each year from vaccine- preventable diseases
• Stringent temperature requirements for storage, transportation, and distribution
oVaccine waste is over 50%
“A recent plane diversion left vaccines sitting in a warehouse for two weeks – all wasted,”
Melanie,
Director of Clinics
17

18. New Vaccine Drying Process
"It means that we can get out to more children in countries where immunization coverage is at only 50%. We can reach 100%.“ John Lloyd
•Freeze Dried Vaccines
oReconstitutes to liquid form at clinics
oNot subject to constraints of “Cold Chain” supply
oWorks with only select vaccines
18

19. Technology Status
•UT Austin filed 1 PCT patent application
o148 countries
•Beta product & commercial prototype available
•Working to apply the method to other vaccines to show broad applicability
"It would no longer be the rule that people living in the remotest areas would be the last to be served, if they are served at all.“
Dr La Force,
Former director of the Meningitis Vaccine Program, set up by WHO
http://www.otc.utexas.edu/publications/TechNews_Spring14.jsp
Dry Vaccine Particles
19

20. Behind the Curve?
Disease Coverage
Temp Stable
Needle
Free
Protected IP
Regulatory Approval
Current Tech
Broad
Some
VAX Tech
Narrow
None
Nova Labs
Narrow
Some
AKTIV-DRY, LLC
Intermediate
Some
Some
StablePharma
Narrow
Some
Some
Vaxxis Nano
Broad
Some
Some
Soligenix
Narrow
Some
PATH Tablet
Narrow
Some
20

21. Nova Labs
-VitRIS and HydRIS® products
-On Market
Stable Pharma -StableVax - 2014 market launch
Soligenix
-ThermoVax
-Focused on BioTerror
-In Trials
AKTIV-DRY
-Dry powders
for vaccines
- On Market
Competitive Threats
21

22. Vaxxas Nanopatch
Eliminates additives, adjuvants
Harvard
On demand vaccines with engineered nanoparticles
PATH
fast-dissolving tablet (FDT) vaccine
Tomorrow’s Technology
“I routinely order 30% overage to compensate for losses & waste $3- $6k per 50k vaccines delivered”
22

23. Potential Market
●Larger market growth happening outside US with poorer economic conditions
●$25.3 billion market in 2010
●$39.5 billion market by 2015
http://www.genengnews.com/Media/images/Article/Nov0111_BioMktTrnds1421311133.jpg
23

24. Next Steps
•Licensing is the way to go
•Reduces the need for investment & infrastructure
•Follow up on domestic market opportunities
•Pursue needle-free packaging
24

25. Licensees & Partners
Serum Institute of India
•Licenses vaccines
•Supplies to WHO, UNICEF, PAHO & > 140 countries
Private Foundations
Public-private partnerships
Aespira Ltd.
• Inhaler product for generic dry powder drugs
25

26. MSTC 2015 Team 15 Members
Daniel Cloud
Liz Shumpert
Brian Wilson
Anthony Mallon
Cheryl Tulkoff
26

27. Quicklook process provides a method for technology commercialization assessment that is:
◦Rapid
◦Affordable
◦Data-driven
Reduces risk of failure
◦Identified the best markets, best customers, partners
Identifies best way to proceed if technology seems viable
27

28. 1.Brett Cornwell (1998). 'Quicklook' commercialization assessments. Innovation: Management, Policy & Practice: Vol. 1, No. 1, pp. 7-9. doi: 10.5172/impp.1998.1.1.7.
2.Cornwell, B. (1997). The RIB-IT View. In T. F. Schoenborn, The RIB-IT Views (pp. 301- 308). US Federal Laboratory Consortium.
3.Quicklook Methodology & Relationship Marketing; Dr. Brad Zehner, July 2012.
4.Mind Map and Demonstration of the Quicklook Methodology for Technology Commercialization; Andrew Paul Harbert, UT Masters Thesis.
5.Jolly, V. K., Commercializing New Technologies: Getting from Mind to Market.
6.Boston: Harvard Business School Press.
7.Rob Adams, If You Build It Will They Come: Three Steps to Test and Validate Any Market Opportunity.
8.If we switch over to start-ups, the failure rate takes a huge leap to 90 percent.
9.Adams, Rob (2010-03-09). If You Build It Will They Come: Three Steps to Test and Validate Any Market Opportunity (p. 2). Wiley. Kindle Edition.
10.http://www.aztekgv.com/index.php/services/reports/quicklook
11.http://www.ic2.utexas.edu/global/services/education/assessment/
12.http://utenportugal.org/wp-content/uploads/Quicklook-Report.pdf
13.https://acc.dau.mil/CommunityBrowser.aspx?id=50609
14.http://www.slideshare.net/cchittim/quicklook-technology-assessment-topmod- softwareccchittim
15.http://www.gao.gov/products/GAO-12-400SP
28

29. Cheryl has over 22 years of experience in electronics manufacturing focusing on failure analysis and reliability. She is passionate about applying her unique background to enable her clients to maximize and accelerate product design and development while saving time, managing resources, and improving customer satisfaction.
Throughout her career, Cheryl has had extensive training experience and is a published author and a senior member of both ASQ and IEEE. She views teaching as a two-way process that enables her to impart her knowledge on to others as well as reinforce her own understanding and ability to explain complex concepts through student interaction. A passionate advocate of continued learning, Cheryl has taught electronics workshops that introduced her to numerous fascinating companies, people, and cultures.
Cheryl has served as chairman of the IEEE Central Texas Women in Engineering and IEEE Accelerated Stress Testing and Reliability sections and is an ASQ Certified Reliability Engineer, an SMTA Speaker of Distinction and serves on ASQ, IPC and iNEMI committees.
Cheryl earned her Bachelor of Mechanical Engineering degree from Georgia Tech and is currently a student in the UT Austin Masters of Science in Technology Commercialization (MSTC) program. She was drawn to the MSTC program as an avenue that will allow her to acquire relevant and current business skills which, combined with her technical background, will serve as a springboard enabling her clients to succeed in introducing reliable, blockbuster products tailored to the best market segment.
In her free time, Cheryl loves to run! She’s had the good fortune to run everything from 5k’s to 100 milers including the Boston Marathon, the Tahoe Triple (three marathons in 3 days) and the nonstop Rocky Raccoon 100 miler. She also enjoys travel and has visited 46 US states and over 20 countries around the world. Cheryl combines these two passions in what she calls “running tourism” which lets her quickly get her bearings and see the sights in new places.
29